About the Authors
Lindsey Griggs, PharmD, is a clinical assistant professor at the University of Missouri-Kansas City School of Pharmacy and an infectious diseases–trained acute care clinical pharmacist practitioner at Harry S. Truman Memorial Veterans’ Hospital in Columbia, Missouri.
Tina Zheng, PharmD, BCIDP, is a clinical pharmacotherapy specialist in infectious diseases and antimicrobial stewardship at NYU Langone Health in New York, New York.
Patricia Saunders-Hao, PharmD, BCIDP, BCPS (AQ-ID), is a senior clinical pharmacy specialist in infectious diseases at North Shore University Hospital in Manhasset, New York, and a site coordinator for the Long Island Jewish Medical Center and North Shore University Hospital PGY2 Infectious Diseases Pharmacy Residency program in New Hyde Park, New York.
Introduction
Vaccines have the potential to prevent disease, hospitalization, and death. A 2024 US report noted that routine childhood vaccinations had prevented more than 500 million cases of illness, 30 million hospitalizations, and
1 million deaths in children born between 1994 and 2023.1 However, childhood vaccination rates are declining worldwide, leading to outbreaks of vaccine-preventable diseases such as measles. In the US, vaccination rates of the measles, mumps, and rubella (MMR) vaccine have fallen in many states, often below the 95% threshold.2
One major driver of decreased immunizations is vaccine hesitancy. The World Health Organization defines vaccine hesitancy as a “delay in acceptance or refusal of safe vaccines despite availability of vaccination services” and listed it in the top 10 global health threats in 2019.3,4 There can be various reasons for vaccine hesitancy, including misinformation and lack of understanding, fear of potential adverse effects (AEs), religious and cultural beliefs, and mistrust in government and in the pharmaceutical industry.5 Understanding and addressing the cause of an individual’s vaccine hesitancy is paramount in combating this issue.
Pharmacists are among the most trusted and accessible health professionals, giving them an opportunity to address vaccine hesitancy. Across every setting, they can rebuild vaccine confidence by combining fluency in evidence, effective conversations, and vetted resources.
The Evidence Base for Vaccinations
Patients encounter vaccine claims constantly, often without context. Pharmacists can build confidence by explaining that vaccines may not prevent every infection but consistently reduce severe illness, hospitalization, and death (Tables 1 and 2).
In adults, influenza, COVID-19, pneumococcal conjugate, and respiratory syncytial virus (RSV) vaccines reduce severe respiratory outcomes such as hospitalization and death. Serious AEs are uncommon. Some effects like myocarditis and pericarditis were observed with pre-2022 COVID-19 vaccination in adolescent and young adult male patients, though these risks were mitigated with a longer dosing interval. Guillain-Barré syndrome is a rare warning for some respiratory vaccines, including RSV, but the benefit-risk balance remains favorable.
In children, influenza, COVID-19, pneumococcal conjugate, and MMR vaccines prevent severe illness and its complications. Maternal RSV vaccination at 32 to 36 weeks’ gestation also reduces infant RSV illness and hospitalization. Serious AEs are uncommon, although certain vaccines carry a small increased risk of febrile seizures or immune thrombocytopenia.
Concerns about vaccine safety include persistent claims that vaccines cause autism. The controversy linking MMR vaccination to autism began with a 1998 case series of 12 children that relied on retrospective parental reports to suggest an association. The report was subsequently retracted, and large epidemiologic studies have found no causal relationship between MMR vaccination and autism.6 Although rare AEs (eg, febrile seizures) can occur, the risks associated with vaccine-preventable infections are greater.
A simple summary pharmacists can share with patients is the following: “No vaccine is completely risk-free, but serious reactions are rare, and vaccination helps prevent the complications we worry about most.”
Effective Conversations: What to Say and How to Say It
Start with a presumptive recommendation and emphasize the social norm.15,16 Treat the vaccine as the expected next step, not an open question. “You’re due for your flu shot today” lands very differently than “Would you like to receive a flu shot?” One assumes yes, whereas the other invites conversation. In one observational study, approximately 74% of parents agreed to vaccinate their children when clinicians used a presumptive opener vs 4% with a participatory approach.16 A confident recommendation from a trusted professional remains a strong predictor of uptake.18 Pharmacists can also note that most people choose to vaccinate: “More than 90% of my patients get this annually.”
Utilize motivational interviewing (MI) when encountering resistance. Ask permission before sharing facts, use open-ended questions, and reflect the patient’s concern rather than overriding it.16 In one MI-based trial, human papillomavirus vaccine series initiation rose by an absolute 9.4 percentage points vs controls, with lower hesitancy scores still measurable months later.19 Rather than reciting a generic script, directly address the patient’s concern by matching your response to the actual worry (eg, safety, necessity, “too many at once”).16,20